Pliant Therapeutics, Inc. (PLRX)
PLRX moved a median of 0.00% 30 minutes after news, and -1.00% by the close. How PLRX actually reacts to news — the realized, point-in-time move the market made, measured across 339 labeled events over the last three years with zero look-ahead.
PLRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 339 |
| 30-min | 0.00% | 45% | 339 |
| 60-min | -0.17% | 46% | 339 |
| to close | -1.00% | 35% | 338 |
| Middle 50% of PLRX reactions | -1.73% to +1.38% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 339 |
Half of all Pliant Therapeutics, Inc. news events land between -1.73% and +1.38% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PLRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 30 | +2.31% | 73% | +1.32% |
| Rating reiterations | 64 | -0.37% | 42% | -1.41% |
| Price-target cuts | 13 | -0.57% | 46% | -0.59% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how PLRX ranks against every other measured name →
That’s how PLRX usually reacts — get an email when it moves on news →Email me when PLRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PLRX's baseline. Nothing else.
Recent PLRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer | Press release | GlobeNewswire | -0.91% | -4.54% | |
| Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors | Press release | GlobeNewswire | +2.99% | -1.71% | |
| Form 10-Q PLIANT THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.35% | +2.88% | |
| Form 8-K PLIANT THERAPEUTICS, For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -1.35% | +2.88% | |
| Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -1.35% | +2.88% | |
| Form 8-K PLIANT THERAPEUTICS, For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | +0.43% | -5.22% | |
| Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors | Press release | GlobeNewswire | +0.00% | +1.79% | |
| Form 8-K PLIANT THERAPEUTICS, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.74% | |
| Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | Press release | GlobeNewswire | +0.81% | -2.42% | |
| Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board | Press release | PR Newswire | -0.87% | +0.00% | |
| Form 10-Q PLIANT THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.67% | |
| Form 8-K PLIANT THERAPEUTICS, For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.67% | |
| Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.00% | -1.67% | |
| Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference | Press release | GlobeNewswire | +0.83% | +2.50% | |
| Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors | Press release | GlobeNewswire | +0.41% | +0.00% | |
| Form ARS PLIANT THERAPEUTICS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -1.56% | |
| Form DEF 14A PLIANT THERAPEUTICS, For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -1.56% | |
| Form DEFA14A PLIANT THERAPEUTICS, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -1.56% | |
| Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | -4.15% | -4.44% | |
| Form 8-K PLIANT THERAPEUTICS, For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | -4.15% | -4.44% | |
| Form EFFECT PLIANT THERAPEUTICS, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +0.77% | |
| Form 8-K PLIANT THERAPEUTICS, For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +2.14% | +7.69% | |
| Form S-3 PLIANT THERAPEUTICS, | SEC filing · Form S-3 | SEC EDGAR | +2.14% | +7.69% | |
| Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | +1.12% | -4.48% | |
| Form 10-K PLIANT THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.38% | +6.01% | |
| Form 8-K PLIANT THERAPEUTICS, For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | +0.38% | +6.01% | |
| Form S-8 PLIANT THERAPEUTICS, | SEC filing · Form S-8 | SEC EDGAR | +0.38% | +6.01% | |
| Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.38% | +6.01% | |
| Form 8-K PLIANT THERAPEUTICS, For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -1.56% | +0.78% | |
| Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference | Press release | GlobeNewswire | +0.81% | -0.81% | |
| Form 8-K PLIANT THERAPEUTICS, For: Dec 10 | SEC filing · Form 8-K | SEC EDGAR | +2.44% | -0.81% | |
| Form 8-K PLIANT THERAPEUTICS, For: Dec 02 | SEC filing · Form 8-K | SEC EDGAR | +3.52% | -1.56% | |
| Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors | Press release | GlobeNewswire | -3.07% | -19.63% | |
| Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference | Press release | GlobeNewswire | -1.26% | -3.77% | |
| Form 10-Q PLIANT THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.31% | +5.96% | |
| Form 8-K PLIANT THERAPEUTICS, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +3.31% | +5.96% | |
| Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +3.31% | +5.96% | |
| Form 8-K PLIANT THERAPEUTICS, For: Oct 20 | SEC filing · Form 8-K | SEC EDGAR | +6.63% | -0.55% | |
| Form 8-K PLIANT THERAPEUTICS, For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +0.88% | +10.00% | |
| Form 10-Q PLIANT THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.85% | +6.41% | |
| Form 8-K PLIANT THERAPEUTICS, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +3.85% | +6.41% | |
| Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | +3.85% | +6.41% | |
| Pliant Therapeutics Provides Update on BEACON-IPF | Press release | GlobeNewswire | +0.00% | -7.20% | |
| Form 8-K PLIANT THERAPEUTICS, For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | -2.19% | -3.75% | |
| Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference | Press release | GlobeNewswire | -1.88% | +0.75% | |
| Form 10-Q PLIANT THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.34% | -2.76% | |
| Form 8-K PLIANT THERAPEUTICS, For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +0.34% | -2.76% | |
| Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.34% | -2.76% | |
| Form 8-K PLIANT THERAPEUTICS, For: May 01 | SEC filing · Form 8-K | SEC EDGAR | +0.91% | +2.42% | |
| Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations | Press release | GlobeNewswire | +0.91% | +2.42% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PLRX section they belong to.
Where else PLRX is measured.
PLRX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Pliant Therapeutics, Inc.'s median reaction calculated?
Every labeled PLRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 339 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of PLRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PLRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.